功能性消化不良 中国就医指南

Functional dyspepsia (FD) is a chronic, heterogeneous disorder of the upper gastrointestinal tract characterized by persistent or recurrent epigastric pain or discomfort—such as burning, early satiety, postprandial fullness, or nausea—in the absence of structural, biochemical, or metabolic abnormalities that could explain the symptoms. It is classified under disorders of gut–brain interaction (formerly functional gastrointestinal disorders) and diagnosed using Rome IV criteria after excluding organic causes like peptic ulcer disease, gastric cancer, gastroesophageal reflux disease (GERD), celiac disease, or Helicobacter pylori infection via endoscopy, serology, breath testing, or histopathology. Pathophysiologically, FD involves complex interplay among visceral hypersensitivity, impaired gastric accommodation and motility (e.g., delayed gastric emptying or antral hypomotility), low-grade mucosal inflammation, altered gut microbiota composition, and central nervous system dysregulation—including heightened perception of normal gastric signals and stress-modulated autonomic and neuroendocrine responses. Psychosocial factors such as anxiety, depression, somatization, and early-life adversity further modulate symptom expression and severity. Epidemiologically, FD affects approximately 10–20% of the global adult population, with regional variation: prevalence in China ranges from 8% to 15%, based on community-based surveys using validated questionnaires. It is more common in women (female-to-male ratio ~1.5:1) and peaks in the third to fifth decades of life. Key risk factors include prior acute gastroenteritis (post-infectious FD), H. pylori infection (even after eradication), smoking, frequent NSAID use, high psychological distress, and dietary triggers (e.g., fatty, spicy, or acidic foods). Unlike organic diseases, FD carries no increased mortality risk—but its chronic, fluctuating nature profoundly impairs quality of life. Patients report significant reductions in work productivity (presenteeism and absenteeism), disrupted sleep, social withdrawal, diminished physical activity, and higher healthcare utilization. Many experience treatment frustration due to symptom recurrence and limited response to conventional therapies, contributing to anxiety about undiagnosed malignancy and reduced health-related quality of life scores comparable to those seen in inflammatory bowel disease or moderate asthma. Early multidisciplinary management—including dietary counseling, pharmacotherapy, cognitive-behavioral strategies, and patient education—is essential to restore functional capacity and prevent long-term disability.

# 功能性消化不良治疗方案与费用明细（消化内科）

一、非手术/保守治疗（一线首选）

• •适用人群：症状轻中度、无报警征象（如消瘦、呕血、黑便、贫血）、幽门螺杆菌阴性或根除后持续者
• •方案构成：饮食行为干预+心理支持+药物治疗（PPI/促动力药/低剂量抗抑郁药）
• •费用明细（三甲医院，单疗程4–8周）：

- 幽门螺杆菌检测（C13/C14呼气试验）：200–350元 - 药物费用（国产PPI+莫沙必利）：280–650元；进口原研药（如埃索美拉唑+伊托必利）：900–1800元

二、微创/介入/核心治疗（二线选择）

• •适用条件：难治性FD伴明显胃排空延迟或内脏高敏感，经规范药物治疗无效≥12周
• •方案：胃电刺激（GES）临床试验性应用（限国家卫健委批准中心）、内镜下胃窦切开术（研究阶段，未常规开展）
• •当前无成熟根治性手术；不推荐腹腔镜/开腹手术——本病属功能性障碍，无解剖结构病变

三、特殊复杂情况处理

• •耐药/反复发作/合并焦虑抑郁：加用SSRIs（如帕罗西汀）、认知行为治疗（CBT门诊）；总费用（含心理评估+6次CBT）：2200–4500元
• •并发症（如营养不良、重度体重下降）：需营养科联合管理+肠内营养支持，月均费用1500–3200元

方案快速选择指南

✅ 首次就诊/预算有限（≤2000元）→ 保守治疗（含呼气试验+国产药） ✅ 症状顽固/伴焦虑（预算3000–6000元）→ 保守治疗+CBT+原研药物 ✅ 疑似器质病变或报警症状 → 必查胃镜（费用1200–2500元，含活检及病理）